Portfolio tactics to scale the $300bn patent cliff
Daniel Chancellor, VP Thought Leadership, Norstella
Daniel Di Gaudio, Senior Associate, Evaluate Consulting & Analytics
The global market for obesity therapeutics has undergone a seismic shift, catalyzed by the rise of GLP-1-based therapies which in turn has driven a surge in strategic dealmaking.
Foreword
The patent cliff situation
The leading culprits
Strategy archetypes for managing patent cliff
Case study
Deal-making alone won’t be sufficient to bridge the gap
How Evaluate Helps